Relative Bioequivalence

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

MoonLake Immunotherapeutics
1 program
1
SonelokimabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT06994936Completed120Est. Nov 2025

Trial Timeline

Clinical trial activity over time

2025
2026
MoonLake ImmunotherapeuticsSonelokimab

Clinical Trials (1)

Total enrollment: 120 patients across 1 trials

NCT06994936MoonLake ImmunotherapeuticsSonelokimab

An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector

Start: Jun 2025Est. completion: Nov 2025120 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space